Drug discovery in academia: the third way?

  title={Drug discovery in academia: the third way?},
  author={Julie A. Frearson and Paul Graham Wyatt},
  journal={Expert Opinion on Drug Discovery},
  pages={909 - 919}
As the pharmaceutical industry continues to re-strategise and focus on low-risk, relatively short-term gains for the sake of survival, we need to re-invigorate the early stages of drug discovery and rebalance efforts towards novel modes of action therapeutics and neglected genetic and tropical diseases. Academic drug discovery is one model which offers the promise of new approaches and an alternative organisational culture for drug discovery as it attempts to apply academic innovation and… 
Intellectual property management in academic drug discovery: what are the challenges?
Some current trends in academic IP management are highlighted, which include generating lead compounds and demonstrating in vivo proof of concept in relevant disease models.
Academic Discovery of Anticancer Drugs: Historic and Future Perspectives
The history of academic-industry interactions in the context of antidrug discovery is discussed and a view of where these interactions are likely headed is offered as the authors continue to reach new horizons in their understanding of the immense complexities of cancer biology.
Pharmaceutical innovation and public policy: The case for a new strategy for drug discovery and development
The major research-intensive pharmaceutical companies (big pharma), are facing a profound crisis. Their R&D expenditures have grown at a staggering rate, while the creation of drugs that represent
Academic drug discovery: current status and prospects
  • J. Everett
  • Biology
    Expert opinion on drug discovery
  • 2015
This review provides an overview of the current status of academic drug discovery groups, their achievements and the challenges they face, together with perspectives on ways to achieve improved outcomes.
Are academic drug discovery efforts receiving more recognition with declining industry efficiency?
There is now strong evidence of a revival in the rate of approval of new drugs which first appeared in 2011 and is now gathering pace with the endorsement of 59 NMEs in 2018, making previous reports of the demise of the Pharma industry appear premature.
Computational Chemistry on a Budget - Supporting Drug Discovery with Limited Resources.
It is outlined how computational methods can help advance drug discovery in a setting with more limited resources and what, based on the experience, are the best practices for these methods.


Drug discovery: new models for industry-academic partnerships.
Drug discovery in jeopardy.
Despite striking advances in the biomedical sciences, the flow of new drugs has slowed to a trickle, impairing therapeutic advances as well as the commercial success of drug companies. Reduced
HTS and hit finding in academia – from chemical genomics to drug discovery
Drug discovery through industry-academic partnerships
  • N. Gray
  • Biology
    Nature chemical biology
  • 2006
Examples of successful academic-industrial partnerships illustrate the ways in which they can enable the discovery of new medicines.
Network pharmacology: the next paradigm in drug discovery.
A new appreciation of the role of polypharmacology has significant implications for tackling the two major sources of attrition in drug development--efficacy and toxicity.
Building a Pharmacological Lexicon: Small Molecule Discovery in Academia
Some of the challenges and opportunities provided by the Molecular Library Screening Centers Network (MLSCN), which is a National Institutes of Health Roadmap Initiative, are presented.
A Wellcome experiment in seeding drug discovery
Take UK£91 million, plant it into 30 drug discovery projects in academic institutes and in industry, and fertilize regularly with expert advice. What do you get? Bethan Hughes investigates.
Is open innovation the way forward for big pharma?
The current, fully integrated business model of large pharmaceutical companies is increasingly considered to be unsustainable, and so new approaches that engage large and small companies, governments
The Need for Precompetitive Integrative Bionetwork Disease Model Building
  • S. Friend
  • Biology
    Clinical pharmacology and therapeutics
  • 2010
Until the authors better understand diseases as altered bionetworks and view diseases at an individual patient level, efforts to develop effective biomarkers and therapies will be inefficient at best.
National origins of new drugs
This analysis attributes a country of discovery to each of the 170 new molecular entities and new therapeutic biological entities approved by the FDA between 1998 and 2003, reflecting the relative strength of the UK biotech sector compared with continental Europe.